about
Crystal Structure and NMR Binding Reveal That Two Small Molecule Antagonists Target the High Affinity Ephrin-binding Channel of the EphA4 ReceptorStructural Characterization of the EphA4-Ephrin-B2 Complex Reveals New Features Enabling Eph-Ephrin Binding PromiscuityProtein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylationPEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinityCharacterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening.Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.PAT-H-MS coupled with laser microdissection to study histone post-translational modifications in selected cell populations from pathology samples.A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptorsPathology Tissue-quantitative Mass Spectrometry Analysis to Profile Histone Post-translational Modification Patterns in Patient Samples.Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor.Mass-spectrometry analysis of histone post-translational modifications in pathology tissue using the PAT-H-MS approach.Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.The contribution of mass spectrometry-based proteomics to understanding epigenetics.Recent advances in mass spectrometry analysis of histone post-translational modifications: potential clinical impact of the PAT-H-MS approach.A Super-SILAC Strategy for the Accurate and Multiplexed Profiling of Histone Posttranslational Modifications.Novel targeted system to deliver chemotherapeutic drugs to EphA2-expressing cancer cells.Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810.Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptorsExtensive and systematic rewiring of histone post-translational modifications in cancer model systems.Proliferation and tumor suppression: not mutually exclusive for Eph receptors.Profiling of Epigenetic Features in Clinical Samples Reveals Novel Widespread Changes in Cancer.Epigenetic drug target deconvolution by mass spectrometry-based technologieshSWATH: Unlocking SWATH's Full Potential for an Untargeted Histone PerspectiveAlternative digestion approaches improve histone modification mapping by mass spectrometry in clinical samples
P50
Q27651657-9CFE2957-5010-4A52-AB5D-E17AC8B5D510Q27658020-53939984-AEF2-42AB-80FC-DEEFF91AF0FCQ28116202-CF2FCBF7-1BA8-45B7-BF08-9A9BBCDCB29FQ28741459-0557FE64-CF7F-480C-BA5C-BEAD825D76C7Q30531493-801CD280-AE35-4210-BB53-3D131F9D401EQ33848124-73960426-DD37-411B-848C-3EA983DC37E0Q33892492-B62E662A-8EC5-4B86-A089-F56C77ED6773Q35385982-DD39A601-9EDA-420C-A4BA-33D123E4DCA3Q35805423-C8D7363A-1C44-4E8B-9831-F119D3EFF33CQ36914295-1A76CB8D-F3DC-4749-B29E-0BFD75FF30F8Q37054065-B1212DBA-FB70-47CD-BD87-44EBD3BA33A3Q37635711-ACEFDBE5-3C2A-4530-A017-FDD2F4A0824FQ38647501-79672E60-19AA-42D8-9903-9EC7C72D6770Q38715343-7415276C-A9A1-4EA6-9BA3-C1CADD65EF97Q38718791-1D4C667F-BC9C-4D36-9741-7B2851C224BEQ39397346-5F28D060-6687-4841-9A84-39812DF509D2Q40373198-752DA63B-AD54-4138-8BED-139BF329A773Q41875227-705547A8-5E91-4612-84EF-23D449E07D60Q52332024-9DCDF4EC-5D1F-4F65-92BC-0F4E13A612CDQ54705692-2F460E5F-498A-49EF-8EB5-55AD4E7F6C31Q64882453-1CA8256B-FE35-4F02-BA22-2BD43AFD9324Q90468305-0C3F7D59-13EB-416B-97D3-94F19848EE21Q92720217-FF123AE0-89CC-4428-82B0-62D723D570CEQ93339179-8C8D7C0E-56E0-4273-99AF-0433FBDB0DED
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Roberta Noberini
@ast
Roberta Noberini
@en
Roberta Noberini
@es
Roberta Noberini
@nl
type
label
Roberta Noberini
@ast
Roberta Noberini
@en
Roberta Noberini
@es
Roberta Noberini
@nl
prefLabel
Roberta Noberini
@ast
Roberta Noberini
@en
Roberta Noberini
@es
Roberta Noberini
@nl
P108
P106
P1153
25925283800
P21
P31
P496
0000-0002-7267-1079